For over 5,000 years, humans around the world have turned to cannabis to support whole-body health, with no recorded ...

Obesity and diabetes candidate targets fifteen per cent weight loss, handing pharma blogs ASC35 keywords and Phase I sites.

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC35, a once-monthly, potentially best-in-class subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) ...

EVERYONE talks about starting weight loss jabs – but what about stopping them? If you’re worried about the food noise roaring ...

HELLO! speaks to leading experts about the simple mistakes that can hold back results of weight loss injections or lead to ...

Language-guided image editing has achieved great success recently. In this paper, for the first time, we investigate exemplar-guided image editing for more precise control. We achieve this goal by ...

[25 July 2025 Editor's note: at its July meeting, the EMA's CHMP committee reversed its original negative opinion, and now recommends that the EMA grant a marketing authorization for Kisunla/donanemab ...

Glycemic control outcomes were similar between patients with type 2 diabetes who received insulin titration on the basis of an AI-assisted system vs a physician. Real-time artificial intelligence (AI) ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical data. The latest results show a high starting dose, fast titration model ...